Synthetic Biologist | Biotech Entrepreneur | MIT Professor
Joined April 2007
- Tweets338
- Following783
- Followers4.6K
- Likes139
Timothy Lu retweeted
Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations, enabled by recent RMAT and Orphan Drug Designations.
bit.ly/3XFf7ST
$SNTI #ASH2025
Thanks to Dr. Farhad Ravandi from @MDAndersonNews for sharing thoughts on the potential for $SNTI's SENTI-202 product to transform the treatment of AML and other cancers. Published by @VJHemOnc vjhemonc.com/video/nvzwt-dus…
Thanks to @GeneOnlineNews for highlighting @SentiBio 's recent SENTI-202 data for R/R AML @ ASH. With 50% ORR, RMAT designation, favorable safety, off-the-shelf delivery, we hope to advance this program quickly into pivotal studies for patients in need
geneonline.com/senti-bio-win…
$SNTI recently reported our Logic Gated SENTI-202 cell therapy achieved 50% ORR, 42% CR/CRh, 7.6 month cCR durability in heavily pretreated refractory/refractory AML patients at #ASH25. This is an exciting new treatment modality for R/R AML, a disease with a median OS ~5 months
Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones.
bit.ly/3XFf7ST
$SNTI #AML #ASH2025
@drpatrick I agree with the power of NK cells. @SentiBio just presented exciting data at #ASH2025 showing that SENTI-202 Logic Gated CAR-NK cells are able to generate deep, durable responses in relapsed/refractory AML with a well tolerated safety profile
Timothy Lu retweeted
If you missed our CEO, Tim Lu, at the H.C. Wainwright 27th Annual Global Investment Conference, don’t worry — you can watch the full presentation now!
🎥 Replay available here: bit.ly/4mK46dE
$SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia
Excited to share updates on Senti Bio’s SENTI-202 program with Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML. Come join us at 830 AM ET webinar! $SNTI investors.sentibio.com/news-…
Timothy Lu retweeted
Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025
bit.ly/3QYtOx5
@AACR
Timothy Lu retweeted
#MarkYourCalendars: $SNTI leadership will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at #AACR2025 on Monday, April 28, 2025, at 8:30 AM ET. Access it here: bit.ly/3S668ap
#CellTherapy #CARNK #AML @AACR
Timothy Lu retweeted
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
bit.ly/3QYtOx5
$SNTI #CellTherapy #CARNK @AACR #AACR25
Excited to share the latest clinical and preclinical data on our Logic Gated SENTI-202 product at the upcoming AACR meeting!
Kanya Rajangam, MD, PhD, President and Chief Medical Officer of $SNTI, shares her excitement for the upcoming data presentation from the SENTI-202 trial at the AACR Annual Meeting being held April 25-30, 2025
bit.ly/3QYtOx5
@AACR